Pluri (PLUR) Stock Overview
A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PLUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.49 |
| 52 Week High | US$23.45 |
| 52 Week Low | US$9.23 |
| Beta | 0.68 |
| 1 Month Change | 10.26% |
| 3 Month Change | -2.87% |
| 1 Year Change | -34.52% |
| 3 Year Change | -64.07% |
| 5 Year Change | -95.08% |
| Change since IPO | -98.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| PLUR | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0.8% | -2.4% | 2.3% |
| 1Y | -34.5% | 10.4% | 49.5% |
Return vs Industry: PLUR underperformed the IL Biotechs industry which returned 13.1% over the past year.
Return vs Market: PLUR underperformed the IL Market which returned 52% over the past year.
Price Volatility
| PLUR volatility | |
|---|---|
| PLUR Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in IL Market | 7.8% |
| 10% least volatile stocks in IL Market | 3.2% |
Stable Share Price: PLUR's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: PLUR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 135 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
Pluri Inc. Fundamentals Summary
| PLUR fundamental statistics | |
|---|---|
| Market cap | ₪107.95m |
| Earnings (TTM) | -₪69.91m |
| Revenue (TTM) | ₪4.11m |
Is PLUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUR income statement (TTM) | |
|---|---|
| Revenue | US$1.33m |
| Cost of Revenue | US$757.00k |
| Gross Profit | US$569.00k |
| Other Expenses | US$23.12m |
| Earnings | -US$22.55m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.26 |
| Gross Margin | 42.91% |
| Net Profit Margin | -1,700.68% |
| Debt/Equity Ratio | -487.7% |
How did PLUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/04 03:10 |
| End of Day Share Price | 2026/02/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pluri Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Christian Orquera | First Berlin Equity Research GmbH |